Apricot Capital is an institutional investor (Conventional VCs) founded in 2017 and headquartered in Singapore, Singapore. Apricot Capital is a leading investment firm deeply rooted in China vibrant healthcare ecosystem, Founded in 2015, the firm has a mission to nurture groundbreaking innovation and bridge the gap between China burgeoning biotech sector and the global healthcare landscape. Apricot Capital specializes in incubating and scaling early- and growth-stage companies in innovative biotech, medtech & life science, and biotech supporting ecosystem poised to address critical unmet global clinical needs. The team brings together 20+ investment professionals with complementary backgrounds in clinical medicine, pharmaceutical analysis, and healthcare operations. VC firm investing in early stage healthcare companies. Assets Under Management (AUM): $45B+ (transaction value). HK), AMBRX (NYSE:AMAM), Argo Biopharma, RemeGen (688331. SH), Sinomab (03618. HK), Junshi Biosciences (01877. HK), MicroPort (00853. HK), EverPace (688351. SH), GenFleet (2595. HK), CirCode, Arnatar, Lumiere Therapeutics, LyncBio, MedLink Therapeutics, Nikegen, Qi Biodesign.

Stage

Early Stage, Early Stage

HQ

Shanghai, china

Founded

2015

Website

http://www.apricot-capital.com

LinkedIn

https://linkedin.com/company/apricot-capital-pte-ltd/about

Preparing to pitch Apricot Capital?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.